ABBV 63.68 Abbvie Inc. Common Stock $ABBV Hit a 52
Post# of 39272
Posted On: 11/11/2014 10:02:29 AM
ABBV 63.68 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 64.08 Currently at 63.68 -0.11 -0.17% With a day low of 63.65 and a total volume of 556,890.
ABBV Abbvie Inc. Common Stock Recent Headline News
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 24 mins ago
JNJ: 108.77 (-0.05), GILD: 107.09 (+0.07), ACHN: 12.89 (+0.04), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - 56 mins ago
JNJ: 108.77 (-0.05), GILD: 107.09 (+0.07), ACHN: 12.89 (+0.04), CNAT: 7.02 (-0.04), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - 1 hr 1 min ago
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.73 (-0.06), ENTA: 44.24 (+0.10)
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - 2 hrs 1 min ago
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.73 (-0.06), ENTA: 44.24 (+0.10)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 328.83 (+0.96), RPRX: 8.81 (-0.41), ABBV: 63.73 (-0.06), AMAG: 34.83 (-0.08)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 328.83 (+0.96), GILD: 107.06 (+0.04), SHPG: 201.84 (+0.86), ABBV: 63.73 (-0.06), CELG: 107.91 (-0.10)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.23 (-0.01), GILD: 107.06 (+0.04), MRK: 59.46 (+0.65), ABBV: 63.73 (-0.06)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.23 (-0.01), EBS: 23.86 (-0.09), ABAX: 53.28 (+0.34), ABBV: 63.73 (-0.06)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.77 (-0.05), GILD: 107.06 (+0.04), ACHN: 12.90 (+0.05), MRK: 59.46 (+0.65), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.06 (+0.04), ACHN: 12.90 (+0.05), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.77 (-0.05), GILD: 107.06 (+0.04), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 106.97 (-0.05), MRK: 59.46 (+0.65), ABBV: 63.73 (-0.06)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.77 (-0.05), GILD: 106.97 (-0.05), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.77 (-0.05), GILD: 106.97 (-0.05), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.77 (-0.05), GILD: 106.97 (-0.05), ACHN: 12.94 (+0.09), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Google's "Cancer Pill": Revolutionary or Ridiculous?
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 1:24PM CST
Google recently unveiled one of its most ambitious healthcare projects ever -- a "smart pill" which scans for cancer cells and other health problems. The pill is loaded with nanoparticles, which are roughly 1/2,000th the size of a red blood cell,...
ABBV: 63.73 (-0.06), GOOGL: 557.49 (-0.74), GOOG: 547.15 (-0.34), ORCL: 40.54 (+0.09), NVS: 92.34 (-0.29)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.29 (+0.07), SGEN: 36.75 (-0.15), GILD: 106.95 (-0.07), ABBV: 63.73 (-0.06), GSK: 45.53 (+0.37)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.23 (-0.01), JNJ: 108.77 (-0.05), GILD: 106.95 (-0.07), ABBV: 63.73 (-0.06)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.23 (-0.01), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), NVS: 92.34 (-0.29)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.23 (-0.01), AZN: 73.93 (+0.72), ABBV: 63.73 (-0.06), AEGR: 20.94 (-0.63)
ABBV Abbvie Inc. Common Stock Recent Headline News
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 24 mins ago
JNJ: 108.77 (-0.05), GILD: 107.09 (+0.07), ACHN: 12.89 (+0.04), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - 56 mins ago
JNJ: 108.77 (-0.05), GILD: 107.09 (+0.07), ACHN: 12.89 (+0.04), CNAT: 7.02 (-0.04), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - 1 hr 1 min ago
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.73 (-0.06), ENTA: 44.24 (+0.10)
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - 2 hrs 1 min ago
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.73 (-0.06), ENTA: 44.24 (+0.10)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 328.83 (+0.96), RPRX: 8.81 (-0.41), ABBV: 63.73 (-0.06), AMAG: 34.83 (-0.08)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 328.83 (+0.96), GILD: 107.06 (+0.04), SHPG: 201.84 (+0.86), ABBV: 63.73 (-0.06), CELG: 107.91 (-0.10)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.23 (-0.01), GILD: 107.06 (+0.04), MRK: 59.46 (+0.65), ABBV: 63.73 (-0.06)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.23 (-0.01), EBS: 23.86 (-0.09), ABAX: 53.28 (+0.34), ABBV: 63.73 (-0.06)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.77 (-0.05), GILD: 107.06 (+0.04), ACHN: 12.90 (+0.05), MRK: 59.46 (+0.65), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.06 (+0.04), ACHN: 12.90 (+0.05), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.77 (-0.05), GILD: 107.06 (+0.04), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 106.97 (-0.05), MRK: 59.46 (+0.65), ABBV: 63.73 (-0.06)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.77 (-0.05), GILD: 106.97 (-0.05), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.77 (-0.05), GILD: 106.97 (-0.05), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.77 (-0.05), GILD: 106.97 (-0.05), ACHN: 12.94 (+0.09), CNAT: 7.02 (-0.04), MRK: 59.46 (+0.65), LGND: 55.88 (+0.20), RGLS: 21.51 (+0.60), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), ENTA: 44.24 (+0.10)
Google's "Cancer Pill": Revolutionary or Ridiculous?
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 1:24PM CST
Google recently unveiled one of its most ambitious healthcare projects ever -- a "smart pill" which scans for cancer cells and other health problems. The pill is loaded with nanoparticles, which are roughly 1/2,000th the size of a red blood cell,...
ABBV: 63.73 (-0.06), GOOGL: 557.49 (-0.74), GOOG: 547.15 (-0.34), ORCL: 40.54 (+0.09), NVS: 92.34 (-0.29)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.29 (+0.07), SGEN: 36.75 (-0.15), GILD: 106.95 (-0.07), ABBV: 63.73 (-0.06), GSK: 45.53 (+0.37)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.23 (-0.01), JNJ: 108.77 (-0.05), GILD: 106.95 (-0.07), ABBV: 63.73 (-0.06)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.23 (-0.01), ABBV: 63.73 (-0.06), BMY: 58.85 (+0.04), NVS: 92.34 (-0.29)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.23 (-0.01), AZN: 73.93 (+0.72), ABBV: 63.73 (-0.06), AEGR: 20.94 (-0.63)
(0)
(0)Scroll down for more posts ▼